Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lundbeck and MSD end gaboxadol development programme

Lundbeck and MSD end gaboxadol development programme

30th March 2007

Lundbeck and Merck, Sharp and Dohme (MSD) have announced the decision to discontinue the companies’ co-development programme for insomnia treatment gaboxadol currently in phase III clinical development.

The companies report that the data from recently conducted trials indicates that the clinical profile of the compound does not support continued development of the drug.

Consequently, Lundbeck and MSD will end all clinical studies involving the compound and not file an application for marketing authorisation for the compound with the European Union or other regulatory bodies.

Peter S Kim, president of MSD research laboratories, said: “The termination of our joint insomnia development programme with Lundbeck is clearly disappointing.”

He added that the partnership agreement between the firms had gained from the robust relationship between the companies, adding that despite this setback, MSD would continue with research programme for sleep disorders and neuroscience, with the firm anticipating working with Lundbeck again on future projects.

Lundbeck noted that work relating to the development of innovative pharmaceutical products is always accompanied by high risks, with today’s announcement being a disappointing one, but not one that would discourage the company from further work to develop novel drugs.

Last October, the companies had announced plans to delay the submission of a new drug application for gaboxadol with the US Food and Drug Administration, citing slower than anticipated enrolment in its phase III trials of the compound.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.